Radar · Gastroenterology in California
Best Gastroenterology Companies in California, United States
The 66 best Gastroenterology companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: NGM Biopharmaceuticals.
By Riya SenguptaFinancials
66companies tracked
$4.3Bdisclosed funding
1unicorns
50have raised
Ranked: Best Gastroenterology companies in California
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | NGM Biopharmaceuticals Developer of biologics for the treatment of cardio-metabolic and liver disease | $359M | 23 mo ago | 225 | 2007 | — | 659 patents Therapeutic antibodies and peptide drugs targeting ILT, glucagon, and GFRAL receptors | — |
| 2 | EndoGastric Solutions Endoluminal solutions for digestive diseases, restoring anatomy and improving patient outcomes | $355M | 54 mo ago | 80 | 2002 | — | 202 patents Surgical devices for gastro‑esophageal valve formation and tissue fastening | — |
| 3 | Denali Therapeutics Developer of therapies to treat neurodegenerative diseases | $347M | 27 mo ago | 377 377 → 582 (+54%) | 2015 | Alexander Schuth Co-Founder | 1,002 patents Neurodegenerative antibody therapies and enzyme‑fusion biologics for lysosomal disease treatment | — |
| 4 | Sonoma Biotherapeutics Developer of T-cell-based therapies for autoimmune and degenerative diseases | $335M | 58 mo ago | 74 74 → 66 (-11%) | 2012 | Fred Ramsdell Co-Founder | 54 patents Engineered immune cell therapies using chimeric antigen receptors and cytokine receptor designs | 1 job opening |
| 5 | Mammoth 🦄 Provider of molecular diagnostics platform by using CRISPR technology | $271M | 57 mo ago | 180 | 2017 | Lucas Harrington Co-Founder & CSO | 3 patents HVAC heating equipment and air‑handling cabinet components | — |
| 6 | Evommune Developer of therapeutic options for chronic inflammatory disorders 60Growth top 16%Funding top 18%News top 25%Tech top 47% All 10 signals ▾Growthtop 16% Fundingtop 18% Newstop 25% Techtop 47% Fin. healthtop 47% Moattop 47% Patentsbottom 47% Marketbottom 46% Innovationbottom 42% Globalbottom 39% Growth: Revenue +86% YoY · Fresh capital in last 24 mo Funding: Raised $268M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 60/100 | $268M | 4 mo ago | 33 | 2020 | — | 3 patents Design of PKCθ inhibitor small molecules for immunomodulatory drug development. | 2 launchs · 1 partnership |
| 7 | Prometheus Laboratories Diagnostics and therapeutics for personalized medicine | $260M | 197 mo ago | 474 474 → 324 (-32%) | 1995 | Joseph Limber President | 49 patents IBD diagnostic and monitoring assays, biomarker profiling, and pharmacokinetic modeling platforms. | — |
| 8 | Terns Pharmaceutical Developer of therapies for treating liver disease and cancer | $208M | 65 mo ago | 46 46 → 66 (+43%) | 2017 | — | — | — |
| 9 | Spyre Therapeutics Developer of monoclonal antibody therapeutics for inflammatory bowel disease | $180M | 30 mo ago | 30 | 2023 | Cameron Turtle CEO | — | 1 award |
| 10 | Ventyx Biosciences Developer of therapeutics to treat autoimmune diseases | $165M | 21 mo ago | 79 | 2018 | Raju Mohan Founder & CEO | 54 patents TYK2 kinase inhibitor design, synthesis, and crystalline forms for immunomodulatory therapeutics | — |
| 11 | Axonics Developer of a device to control urinary and bowel movement | $143M | 98 mo ago | 762 | 2013 | Raymond Cohen CEO | 124 patents Implantable neurostimulation devices and MRI‑compatible leads with external pulse‑generator systems. | — |
| 12 | Prometheus Biosciences Developer of drugs for gastrointestinal diseases | $130M | 67 mo ago | 18 | 2016 | Stephan Targan Co-Founder | 268 patents Biologics targeting TL1A and CD30L for inflammatory disease therapeutics | — |
| 13 | CapsoVision GI capsule imaging system | $118M | 73 mo ago | 68 68 → 108 (+59%) | 2006 | — | 124 patents Capsule endoscopy hardware, power optimization, and AI-driven gastrointestinal image analysis | — |
| 14 | Biora Therapeutics Developer of smart pills for targeted drug delivery to treat gastrointestinal diseases | $117M | 30 mo ago | 54 | 2010 | Adi Mohanty CEO | — | — |
| 15 | Neurogastrx Developer of a dopamine receptor antagonist to treat gastrointestinal disorders | $105M | 57 mo ago | 13 | 2012 | — | 42 patents Metopimazine drug development: polymorphs, metabolic processing, and GI disorder therapies. | — |
| 16 | Emmaus Medical Developer of small molecule therapeutics for the treatment of sickle cell anemia and sickle ß0-thalassemia | $89M | 47 mo ago | 44 | 2000 | — | — | — |
| 17 | Cogentus Pharmaceuticals Drugs for gastrointestinal side effects associated with dual antiplatelet therapy | $78M | 222 mo ago | — | 2006 | Mark Goldsmith President and CEO | — | — |
| 18 | Novome Biotechnologies Developer of gene therapies to treat GI diseases | $77M | 45 mo ago | 44 | 2015 | Will DeLoache Co-Founder | 37 patents Engineered microbial therapeutics and recombinant protein secretion for gut and bile‑acid treatments | — |
| 19 | Xlumena Innovative medical solutions transforming lives through interventional EUS therapeutics | $74M | 138 mo ago | 2 | 2008 | — | 67 patents Endoscopic tissue anchoring and anastomosis devices for minimally invasive gastrointestinal surgery | — |
| 20 | Protagonist Therapeutics Developer of oral peptide therapeutics for gastrointestinal diseases | $67M | 34 mo ago | 112 112 → 157 (+40%) | 2001 | Dinesh Patel CEO & President | 497 patents Peptide therapeutics targeting IL‑23, hepcidin mimetics for iron disorders, and metabolic agonists. | — |
| 21 | Avantis Visualization technology for detection and prevention of GI cancers | $63M | 99 mo ago | 7 | 2004 | — | — | — |
| 22 | Ardelyx Developer of therapeutics for the gastrointestinal tract, cardio-renal, GI, and metabolic diseases | $61M | 47 mo ago | 37 | 2007 | Peter G Schultz Co-Founder | 410 patents Oral phosphate transport inhibitors and formulations for kidney disease and hyperkalemia | 1 job opening · 1 internship |
| 23 | ARYx Therapeutics Retro Metabolic Drug design to retain efficacy | $55M | 190 mo ago | 56 | 1997 | — | — | — |
| 24 | Meritage Pharma Phase III-ready rare disease drug for gastrointestinal and atopic diseases | $36M | 175 mo ago | 6 | 2008 | — | — | — |
| 25 | Averto Medical Developer of medical devices for patients suffering from gastrointestinal diseases | $33M | 21 mo ago | 18 | 2016 | Kenton Fong Founder & CEO | — | — |
| 26 | C2 Therapeutics Speciality company thear develops ablation therapies for GI tract infections | $29M | 114 mo ago | 16 | 2007 | — | 1,872 patents Patents concentrated in chemistry & materials | — |
| 27 | Athos Therapeutics Developer of AI-based therapeutics for treating autoimmune diseases 35AI top 35%Funding top 36%Talent bottom 49%Moat bottom 45% All 6 signals ▾AItop 35% Fundingtop 36% Talentbottom 49% Moatbottom 45% Marketbottom 32% Globalbottom 25% AI: Product described with: ai-based, machine learning Funding: Raised $28.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $28M | 2 mo ago | 18 | 2019 | Dimitrios Iliopoulos Co-founder | — | — |
| 28 | Lyric Pharmaceuticals Therapeutics for gastrointestinal indications | $28M | 110 mo ago | 7 | 2013 | — | — | — |
| 29 | Gemelli Biotech Precision diagnostics for gastrointestinal diseases, leveraging microbiome discoveries for optimal treatment | $21M | 54 mo ago | 27 | 2018 | Kapil Gupta Co-Founder & Scientific Advisor | — | — |
| 30 | Ritter Pharmaceuticals Developer of therapeutics to treat gastrointestinal diseases | $21M | 91 mo ago | 5 | 2004 | Michael Poirier CEO | — | — |
| 31 | Integrated Endoscopy Innovating single-use wireless endoscopy for enhanced surgical solutions and patient safety | $20M | 93 mo ago | 5 | 1996 | — | 54 patents Disposable, wireless endoscopic imaging devices with interchangeable cannula adapters. | — |
| 32 | Boomerang Medical Bioelectronic device technology for the treatment of autoimmune diseases | $18M | 9 mo ago | 5 | 2021 | — | — | 1 internship |
| 33 | Rejuvenation Technologies Developer of nucleoside-modified TERT mRNA for antiaging | $15M | 13 mo ago | 12 | 2012 | Glenn Markov Co-Founder | — | — |
| 34 | Barrx Medical Ablation technology for Barrett's Esophagus treatment | $15M | 191 mo ago | 26 | 2003 | — | — | — |
| 35 | Evoke Pharma Pharmaceutical company focused on gastrointestinal diseases, improving patient lives | $14M | 144 mo ago | 4 | 2007 | Matthew DOnofrio Co-Founder & CBO | — | — |
| 36 | Napo Pharma Develops small molecule therapeutics for diarrheal diseases | $13M | 113 mo ago | 7 | 2001 | Lisa Conte Founder & CEO | — | — |
| 37 | Jaguar Health Developing gastrointestinal products for human prescription use and animals 50Product top 14%Funding top 24%Innovation top 34%Growth top 43% All 11 signals ▾Producttop 14% Fundingtop 24% Innovationtop 34% Growthtop 43% Talentbottom 49% Marketbottom 48% Fin. healthbottom 48% Moatbottom 45% Newsbottom 41% Techbottom 33% Globalbottom 32% Product: 4 distinct product lines · Company stage: Public Funding: Raised $11.6M across 28 rounds · 28 rounds over 12 yrs (2.3/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $12M | 5 mo ago | 46 46 → 35 (-24%) | 2013 | Lisa Conte Founder & CEO | — | 1 launch · 1 partnership |
| 38 | Particella Developer of gene therapies for gastrointestinal diseases | $7M | 50 mo ago | 4 | 2016 | Timothy Day Co-Founder | 3 patents Advanced biologic drug delivery systems and formulations for therapeutic agents | — |
| 39 | Palisade Bio Developer of therapeutics for gastrointestinal complications | $7M | 5 mo ago | 12 | 2005 | Thomas Hallam CEO | — | — |
| 40 | Ictero Medical Developer of a device for gall stone surgical removal procedure | $7M | 49 mo ago | 6 | 2018 | David Waters Co-Founder & COO | — | — |
| 41 | G-Tech Medical Wireless GI diagnostics improving gastrointestinal disorder treatment through advanced technology | $7M | 72 mo ago | 5 | 2010 | — | 1,900 patents Patents concentrated in health & consumer products | — |
| 42 | Altay Therapeutics Developer of therapeutics for chronic liver diseases and cancer | $7M | 17 mo ago | 7 | 2019 | Osman Ozes Founder & CSO | — | — |
| 43 | Halo Biosciences Developer of therapies by editing extracellular matrix | $5M | 14 mo ago | 12 | 2019 | Andy Wardle Co-Founder & Advisor | — | — |
| 44 | Gravitas Medical Provider of Naso-gastric feeding system that measures gastric residual volume | $5M | 61 mo ago | 8 | 2015 | Daniel Burnett Co-Founder & CMO | — | — |
| 45 | GI Logic Innovative gastrointestinal health solutions through wearable biosensors and advanced technology | $4M | 121 mo ago | — | 2013 | James Beeton Co-Founder & Co-CEO | — | — |
| 46 | Avexegen Therapeutics Novel peptide therapies to treat inflammatory bowel disease (IBD) and necrotizing enterocolitis (NEC). | $750K | 64 mo ago | — | 2015 | Soumitra Ghosh Co-Founder & CSO | — | — |
| 47 | Triursus Therapeutics Developer of novel monoclonal antibodies to treat IBD | $452K | 64 mo ago | — | 2017 | Rosemarie DeKruyff Co-Founder | — | — |
| 48 | Pleiogenix Developer of therapeutics for the treatment of liver diseases | $296K | 49 mo ago | — | 2018 | Joseph Evans Co-Founder & CEO | 6 patents Therapeutic application of indeglitazar for treating liver fibrosis and related conditions. | — |
| 49 | Empire Biotechnologies Penetrex: Effective cream for muscle and joint pain relief | $210K | 94 mo ago | 2 | 2013 | — | — | — |
Top 12 Gastroenterology companies in California
#1
Public · Sacramento, California · founded 2020 · 33 employees$268Mraised▾
Public · Sacramento, California · founded 2020 · 33 employees
Developer of therapeutic options for chronic inflammatory disorders. The pipeline drug candidates include v for rosacea, and atopic dermatitis, RORγt for psoriasis, MRGPRX2 for pruritus, and PKCϴ for atopic dermatitis. The company uses a tissue-based screening platform that helps in the drug development of inflammatory diseases.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Growth
top 16%Funding
top 18%News
top 25%Tech
top 47%Fin. health
top 47%Moat
top 47%Growth: Revenue +86% YoY · Fresh capital in last 24 mo
Funding: Raised $268M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) · Last round Post IPO (Feb 2026)
News: 15 BI events in 12 mo (of 26 tracked, 6 types) · +650% YoY · 14 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 5k LinkedIn followers — 2.5% of this cohort's audience
Activity (LinkedIn): 2 product launches · 1 partnerships (incl. Maruho Co Ltd.) announced in 12 mo
Funding rounds
- Feb 2026Post IPO$125M
- Oct 2024Series C$115M
- Jun 2023Series B$7.5M
- Mar 2023Series B$57.5M
Investors
Andera Partners, Life Sciences Partners, Pivotal bioVenture Partners, RA Capital Management, Sectoral, RTW Investments
Tech stack
Amazon Web ServicesAosApache Http ServerBootstrapCloudflareCloudflare Bot Management
#2
Series A · Torrance, California · founded 2019 · 18 employees$28Mraised▾
Series A · Torrance, California · founded 2019 · 18 employees
Developer of AI-based therapeutics for treating autoimmune diseases. The company has developed an innovative computational process based on machine learning algorithms that identify novel and safe drug/gene targets for individual patients. The product pipeline includes ATH-63, ATH-105, and ATH-120 for Ulcerative Colitis & Crohn’s Disease.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
AI
top 35%Funding
top 36%Talent
bottom 49%Moat
bottom 45%Market
bottom 32%Global
bottom 25%AI: Product described with: ai-based, machine learning
Funding: Raised $28.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series A (Apr 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 2k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Director of AI & Machine Learning
Funding rounds
- Apr 2026Series A$10.3M
- Jan 2024Series A$7.6M
- Nov 2021Series A$20.4M
Founders & team
#3
Public · San Francisco, California · founded 2013 · 46 employees$11.6Mraised▾
Public · San Francisco, California · founded 2013 · 46 employees
Jaguar Health is engaged in developing novel, sustainably derived gastrointestinal products for humans and animals. The company focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Canalevia is the company's lead animal prescription drug product candidate intended for the treatment of various forms of diarrhea in dogs and Equilevia is Jaguar's non-prescription product for total gut health in equine athletes.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Product
top 14%Funding
top 24%Innovation
top 34%Growth
top 43%Talent
bottom 49%Market
bottom 48%Product: 4 distinct product lines · Company stage: Public
Funding: Raised $11.6M across 28 rounds · 28 rounds over 12 yrs (2.3/yr) · Last round Grant (prize money) (Jan 2026)
Innovation: 4 product lines
Audience (LinkedIn): 5k LinkedIn followers — 2.3% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. Japan Health and Filament Health) announced in 12 mo
Funding rounds
- Jan 2026Grant (prize money)$240K
- Sep 2025Post IPO$2.4M
- Feb 2023Post IPO—
- Jul 2022Post IPO$300K
Founders & team
Investors
Sagard Holdings, Hercules Capital, Napo Pharma, FDA
Tech stack
WordpressMysqlPhpBootstrapYoast SeoNginx
#4
Public · Carlsbad, California · founded 2005 · 12 employees$7.3Mraised▾
Public · Carlsbad, California · founded 2005 · 12 employees
Developer of therapeutics for gastrointestinal complications. The company's lead candidate GT-2108 is a microbiota-activated PDE4 inhibitor prodrug for the treatment of moderate-to-severe ulcerative colitis. Other drug is GT-1908 for fibrostenotic crohn’s disease.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers
Funding rounds
- Jan 2026Post IPO$500K
- May 2024Post IPO$4M
- Dec 2022Post IPO—
- May 2022Post IPO$2.4M
Founders & team
Investors
Yumaregional, HHS, Crohn's & Colitis Foundation, Business Innovation Network
Tech stack
AccessibeCloudflareCookieyesDiviFlywheelGoogle Analytics
#5
Public · San Francisco, California · founded 2007 · 225 employees$358.9Mraised▾
Public · San Francisco, California · founded 2007 · 225 employees
Developer of biologics for the treatment of cardio-metabolic and liver diseases. The drug candidate NGM282 is used for the treatment of bile acid-related diseases; non-alcoholic steatohepatitis. It also develops novel drug candidates for the treatment of Type 2 diabetes and obesity.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 11k LinkedIn followers — 5.1% of this cohort's audience
Activity: 1 partnerships (incl. PSS) announced in 12 mo
Funding rounds
- Jul 2024Post IPO$142M
- Mar 2015Series D$106M
- Feb 2015Series D$57.5M
- Jul 2013Series C$50M
Investors
Prospect Venture Partners, Rho Capital Partners, Topspin Consumer Partners, The Column Group, Merck, Tichenor Ventures
Tech stack
WordpressMysqlPhpYoast SeoNginxOnetrust
#6
Series B · Mountain View, California · founded 2021 · 5 employees$18Mraised▾
Series B · Mountain View, California · founded 2021 · 5 employees
Bioelectronic device technology for the treatment of autoimmune diseases. It offers a neuromodulation device for treating inflammatory bowel disease through parasympathetic nervous system stimulation.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Sep 2025Series B$20M
- Nov 2022Series A$15M
Investors
Arboretum Ventures, Hatteras Venture Partners
#7
Acquired · Encinitas, California · founded 2018 · 79 employees$165.3Mraised▾
Acquired · Encinitas, California · founded 2018 · 79 employees
Developer of therapeutics to treat autoimmune diseases. The company's pipeline drugs include VTX958 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002 S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735 peripheral inhibitor of the NLRP3 inflammasome. These drugs are used for the treatment of autoimmune disorders by regulating the innate and adaptive immunity to activate type 1 interferon, IL-12, and IL-23 signaling.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 7k LinkedIn followers — 3.3% of this cohort's audience
Funding rounds
- Sep 2024Post IPO$27M
- Sep 2022Post IPO$176.6M
- Sep 2021Series B$51M
- Mar 2021Series B$114.3M
Founders & team
Investors
Third Point, RTW Investments, Janus Henderson Investors, Wellington, Orbimed, VenBio
#8
Seed · Mountain View, California · founded 2012 · 12 employees$15.2Mraised▾
Seed · Mountain View, California · founded 2012 · 12 employees
Rejuvenation Technologies is developing nucleoside-modified TERT mRNA. The nucleoside-modified TERT mRNA is used to extend the telomeres. It is based on the technology that telomere shortening affects cell function. The company has developed in-vivo based therapeutics (in-vivo testing phase) and cell therapies (out-licensing phase) for aging and treating fatal diseases.
Funding rounds
- Apr 2025Grant (prize money)—
- Sep 2024Grant (prize money)$325K
- Aug 2024Grant (prize money)$1.1M
- Oct 2023Seed—
Founders & team
Investors
Khosla Ventures, Shanda, Asymmetry Ventures, Merchant Adventure Investment Advisors, Longevitytech.fund, Y Combinator
Tech stack
WordpressMysqlPhpAstraWpformsJetpack
#9
Public · San Francisco, California · founded 2015 · 377 employees$347Mraised▾
Public · San Francisco, California · founded 2015 · 377 employees
Developer of therapies to treat neurodegenerative diseases. The company's product pipeline includes a small molecule inhibitor of RIP1 kinase to treat Alzheimer's and ALS by regulating inflammatory signaling and affecting glial dysfunction in the brain. Also, provides an LRRK2 inhibitor to treat Parkinson's disease.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 65k LinkedIn followers — 30.7% of this cohort's audience · 538 engagements/post (9.4× cohort median)
Funding rounds
- Feb 2024Post IPO$499.7M
- Aug 2016Series B$130M
- May 2015Series A$217M
Founders & team
Investors
Arch Venture Partners, F-Prime Capital, Alaska Permanent Fund, Flagship Pioneering, Baillie Gifford, Google Ventures
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAmazon CloudfrontAmazon S3Amazon Web ServicesApollo
#10
Series A · Fremont, California · founded 2016 · 18 employees$33Mraised▾
Series A · Fremont, California · founded 2016 · 18 employees
Developer of medical devices for patients suffering from gastrointestinal diseases. The company's products include ColoSeal intraluminal colonic diversion system, enables procedures such as colorectal cancer resection without the need to create an invasive temporary diverting stoma.
Funding rounds
- Sep 2024Grant (prize money)$838.2K
- May 2024Series A$30M
- Nov 2023Seed$3M
- Aug 2021Grant (prize money)$353.5K
Founders & team
Investors
Synergy Ventures, AlwaysraiseVentures, LifeSci Venture Partners, Venrock, Cormorant Asset Management, HHS
#11
Seed · San Francisco, California · founded 2019 · 7 employees$6.7Mraised▾
Seed · San Francisco, California · founded 2019 · 7 employees
Developer of therapeutics for chronic liver diseases and cancer. The product pipeline includes CP4 in the in vivo stage for the treatment of liver cancer and fibrosis; and PCE-0034 for the treatment of prostate cancer and Ewing's sarcoma. It is also focusing on the treatment of chronic inflammatory liver diseases such as NASH and liver cancer.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Jan 2025Grant (prize money)$399.9K
- Jan 2025Grant (prize money)$298.8K
- May 2024Grant (prize money)$300K
- Sep 2023Grant (prize money)$275K
Founders & team
Investors
Y Combinator, Solve FSHD, HHS, gray-trust.com, Tachyon Ventures
#12
Funding Raised · Stanford, California · founded 2019 · 12 employees$5Mraised▾
Funding Raised · Stanford, California · founded 2019 · 12 employees
Developer of therapies by editing extracellular matrix. The lead product H01 is a small-molecule drug that inhibits the synthesis of hyaluronan and treats respiratory conditions like ARDS. Other therapeutic H02 also inhibits hyaluronan synthesis and is in development for lung, liver, diabetes, and metabolic diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 536 LinkedIn followers
Funding rounds
- Mar 2025Grant (prize money)$3M
- May 2024Grant (prize money)$2M
Founders & team
Investors
HHS, QB3
Funding & investor landscape
$4.3Btotal disclosed funding
50companies funded
272disclosed rounds
1rounds last 90 days
Most active investors
Notable founders
Dimitrios Iliopoulos
Co-founder · Athos Therapeutics
Lisa Conte
Founder & CEO · Jaguar Health
Thomas Hallam
CEO · Palisade Bio
Raju Mohan
Founder & CEO · Ventyx Biosciences
Glenn Markov
Co-Founder · Rejuvenation Technologies
John Ramunas
Co-Founder & CEO · Rejuvenation Technologies
Alexander Schuth
Co-Founder · Denali Therapeutics
Kenton Fong
Founder & CEO · Averto Medical
Savage Bates
Owner · Averto Medical
Osman Ozes
Founder & CSO · Altay Therapeutics
Ali Ozes
Founder & CEO · Altay Therapeutics
Andy Wardle
Co-Founder & Advisor · Halo Biosciences
Prism market signals · United States · country-scoped Prism corpus, 11,095,885 docs
Market landscape — 10 sub-themes by coverage
Share of Gastroenterology coverage by sub-theme.
Regulatory-risk over time flat
Funding & growth over time
funding rising · growth rising
Common questions
How many Gastroenterology companies are there in California, United States?
Radar tracks 66 indexable Gastroenterology companies headquartered in California, United States that meet our profile-completeness bar.
What is the total funding raised by Gastroenterology companies in California, United States?
The Gastroenterology companies in California, United States on this list have raised a combined $4.3B in disclosed equity funding across 50 funded companies.
Which is the highest-funded Gastroenterology company in California, United States?
NGM Biopharmaceuticals is the highest-funded Gastroenterology company in California, United States, with $358.9M in disclosed equity funding.
How many Gastroenterology companies in California, United States are funded?
50 of the 66 Gastroenterology companies in California, United States on this list have disclosed at least one equity funding round.
How many Gastroenterology unicorns are there in California, United States?
1 Gastroenterology company in California, United States on this list is valued at $1B or more.
Who are the top investors in California, United States Gastroenterology companies?
The most active investors in California, United States Gastroenterology companies on this list include HHS, Foresite Capital, RTW Investments, Orbimed, Cormorant Asset Management.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.